# Ipamorelin Doses Studied: Routes, Half-Life, Context | Ipamorelin

> Ipamorelin doses studied in the research: human IV PK ranges, the failed trial's regimen, rodent SC doses, half-life ~2 h, and route considerations. Research context only.

Research context only. What was given, to which species, by which route — never a human protocol.

## The short version

This page describes what researchers gave to animals and to trial volunteers. It is not a how-to and it is not a recommendation. No human dose for ipamorelin is established, because the compound is not approved and the one human trial that tested a dose for an outcome did not work [3].

In plain terms: the human studies used a vein (IV), the animal studies mostly used a shot under the skin (subcutaneous) or into the belly, and the drug clears the body fast — roughly a two-hour half-life, meaning the blood level falls by half about every two hours [2]. The popular community routine of pairing it with CJC-1295 and injecting under the skin has no published human dosing basis at all. Where there is no number, this page says so rather than inventing one.

## Doses used in the studies

Stated as studied, third person, by species and route:

- **Human PK/PD study:** 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg, IV over 15 minutes, single doses [2].
- **Human Phase 2 ileus trial:** 0.03 mg/kg IV twice daily for up to 7 days [3].
- **Rat bone-growth study:** 18, 90, and 450 micrograms per day, subcutaneous, divided three times daily, 15 days [4].
- **Rat bone-mineral study:** 0.5 mg/kg/day, continuous subcutaneous by osmotic minipump, 12 weeks.
- **Rat postoperative-ileus model:** 0.1–1 mg/kg IV, repeated four times daily.
- **Ferret cachexia study (2024):** 1–3 mg/kg, intraperitoneal [5].

These are experimental exposures in defined models. None is a human-use instruction.

## Half-life and the GH pulse

In healthy human volunteers, ipamorelin showed a terminal half-life of about 2 hours (IV), with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg [2]. The GH response is a single discrete pulse peaking at roughly 40 minutes (0.67 h) after dosing, then declining [2]. In rats, plasma clearance is roughly five-fold lower than GHRP-6. The short half-life is also why anti-doping reviewers flag it as an analytical challenge to detect [11]: it does not linger.

## Routes studied

The research used several routes, with markedly different efficiency:

- **Intravenous** — human PK and the clinical trial; rodent efficacy [2][3].
- **Subcutaneous** — rodent bone and body-composition studies, and the dominant route in community use [4].
- **Intranasal** — characterized in rodents at roughly 20% bioavailability.
- **Intraperitoneal** — rodent and ferret efficacy studies [5].
- **Oral** — only for engineered ipamorelin-derived analogs (around 10% in dog); ipamorelin itself is not orally bioavailable. See [route notes](/oral).

## How much cjc-1295 ipamorelin should i take

There is no answerable dose. The question "how much cjc-1295 ipamorelin should i take" has no evidence-based answer: no controlled human trial has ever tested the CJC-1295 + ipamorelin combination for any outcome, so no studied human dose exists for the stack [3]. The community subcutaneous protocols that circulate online are anecdotal, have no peer-reviewed human dosing basis, and are not described here as recommendations. This site reports what studies measured; it does not issue protocols, and it does not tell anyone what to take.

## How to reconstitute cjc-1295 ipamorelin 5mg

As a general research-handling observation — not a preparation instruction — ipamorelin is supplied as a lyophilized (freeze-dried) powder, free base or acetate salt, and is reconstituted with bacteriostatic water for laboratory handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These notes come from the research-supply literature and describe how the material behaves; they are not a clinical compounding procedure and not guidance for human use. The pharmacokinetic basis above [2] is the only human-relevant quantitative anchor.

---

A terminal-plain readout of where ipamorelin stands with regulators — never approved, banned in sport, compounding restricted, each line logged to source; no clinic behind the console and nothing here stocked, dispensed, or sold.